Cell state transitions drive the evolution of disease progression in B-lymphoblastic leukemia
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Cancer stem cells (CSCs) are hypothesized to promote tumor progression through innate chemoresistance and self-renewal. CSCs reside in the CD34 + /CD38 - immunophenotypic subpopulation of acute myeloid leukemia (AML); correspondingly, the size of this subpopulation has a strong negative impact on overall survival. Isolation of CSCs from B-lymphoblastic leukemia (B-ALL) has proven difficult, and the cells of interest apparently are not isolated to the CD34 + /CD38 - compartment. This may be explained, in part, by temporal variations of CD34 and CD38 expression which result in stochastic cell state transitions (e.g., from CD34 + /CD38 + to CD34 + /CD38 - ). We present a mathematical model of these transitions and correlate salient findings with BCR::ABL1 status, minimal residual disease (MRD), and relapse in adult B-ALL. As the CSC hypothesis is well supported in AML, we focus on transitions to and from the hematopoietic stem cell compartment (CD34 + /CD38 - ), which our findings suggest can be estimated from peripheral blood or bone marrow samples. Additionally, we find that BCR::ABL1 positive patient samples are associated with high transition rates into the CD34 + /CD38 - compartment, including self-renewal. In contrast, BCR::ABL1 negative patient samples have low CD34 + /CD38 - self-renewal rates and either high CD34 + /CD38 + or CD34 - /CD38 + incoming rates. High CD34 + /CD38 - self renewal is also associated with MRD post-induction chemotherapy. We find a lack of observable changes in cell state transitions between diagnosis and relapse specimens. Our analysis provide evidence of de-differentiation transitions to a CD34+/CD38-stem cell-like immunophenotype in leukemia samples collected from B-ALL patients, and the tendency for these transitions is especially strong for B-ALL with BCR::ABL1. The modeling framework used here is a novel, useful tool to infer both prognosis and genotype from routine flow cytometry data.
Significance Statement
Flow cytometry characterization of B-lymphoblastic leukemia samples (diagnosis, remission, relapse) is used to parameterize a mathematical model of cell state transition rates and stratify patients at risk for post-induction chemotherapy minimal residual disease.